Clinical Data

Soccer ball flying into a net scoring a goal
Biotech

Sellas’ AML asset tied to 50% response rate in certain patients

Sellas’ investigational CDK9 inhibitor has scored in a midstage AML study, demonstrating an ORR of more than double the 20% goal.
Gabrielle Masson Jul 15, 2025 10:34am
obesity overweight weight loss weigh

Hengrui's GLP-1/GIP agonist posts 18% weight loss in ph. 3 trial

Jul 15, 2025 9:17am
Arrows hitting targets

Takeda narcolepsy blockbuster hopeful secures double ph. 3 wins

Jul 14, 2025 5:51am
bet poker chips las vegas betting gamble

AstraZeneca’s $1.3B hypertension med bet pays off with ph. 3 win

Jul 14, 2025 4:09am
An arrow incrementally going up stairs before pointing straight up Blue background

Rhythm’s obesity pill trial hits primary goal, sending stock up

Jul 9, 2025 10:21am
Goal disorientation and lack of vision

UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss

Jul 8, 2025 10:17am